JP2011505835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505835A5 JP2011505835A5 JP2010538155A JP2010538155A JP2011505835A5 JP 2011505835 A5 JP2011505835 A5 JP 2011505835A5 JP 2010538155 A JP2010538155 A JP 2010538155A JP 2010538155 A JP2010538155 A JP 2010538155A JP 2011505835 A5 JP2011505835 A5 JP 2011505835A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- sequence
- nucleic acid
- site
- retroviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 15
- 230000001177 retroviral effect Effects 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 230000002950 deficient Effects 0.000 claims 10
- 230000010354 integration Effects 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 230000006798 recombination Effects 0.000 claims 9
- 238000005215 recombination Methods 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 238000004806 packaging method and process Methods 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 6
- 230000010076 replication Effects 0.000 claims 6
- 241001430294 unidentified retrovirus Species 0.000 claims 6
- 230000026683 transduction Effects 0.000 claims 5
- 238000010361 transduction Methods 0.000 claims 5
- 238000012546 transfer Methods 0.000 claims 5
- 102000018120 Recombinases Human genes 0.000 claims 3
- 108010091086 Recombinases Proteins 0.000 claims 3
- 102000008579 Transposases Human genes 0.000 claims 3
- 108010020764 Transposases Proteins 0.000 claims 3
- 230000002463 transducing effect Effects 0.000 claims 3
- 108010077544 Chromatin Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 210000003483 chromatin Anatomy 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 1
- 230000007067 DNA methylation Effects 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 240000007019 Oxalis corniculata Species 0.000 claims 1
- 108091027981 Response element Proteins 0.000 claims 1
- 241001492360 Retroviral provirus Species 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108700004025 env Genes Proteins 0.000 claims 1
- 101150030339 env gene Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 230000001124 posttranscriptional effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US711807P | 2007-12-11 | 2007-12-11 | |
| US61/007,118 | 2007-12-11 | ||
| PCT/US2008/086409 WO2009076524A2 (en) | 2007-12-11 | 2008-12-11 | Polypurine tract modified retroviral vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015013974A Division JP6001702B2 (ja) | 2007-12-11 | 2015-01-28 | ポリプリントラクト改変レトロウイルスベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011505835A JP2011505835A (ja) | 2011-03-03 |
| JP2011505835A5 true JP2011505835A5 (enExample) | 2012-02-02 |
| JP5749014B2 JP5749014B2 (ja) | 2015-07-15 |
Family
ID=40756119
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538155A Expired - Fee Related JP5749014B2 (ja) | 2007-12-11 | 2008-12-11 | ポリプリントラクト改変レトロウイルスベクター |
| JP2015013974A Expired - Fee Related JP6001702B2 (ja) | 2007-12-11 | 2015-01-28 | ポリプリントラクト改変レトロウイルスベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015013974A Expired - Fee Related JP6001702B2 (ja) | 2007-12-11 | 2015-01-28 | ポリプリントラクト改変レトロウイルスベクター |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9796987B2 (enExample) |
| EP (2) | EP2222861B1 (enExample) |
| JP (2) | JP5749014B2 (enExample) |
| CY (1) | CY1119905T1 (enExample) |
| DK (1) | DK2222861T3 (enExample) |
| ES (1) | ES2664988T3 (enExample) |
| HR (1) | HRP20180184T1 (enExample) |
| HU (1) | HUE036103T2 (enExample) |
| LT (1) | LT2222861T (enExample) |
| NO (1) | NO2222861T3 (enExample) |
| PL (1) | PL2222861T3 (enExample) |
| PT (1) | PT2222861T (enExample) |
| RS (1) | RS56844B1 (enExample) |
| SI (1) | SI2222861T1 (enExample) |
| TR (1) | TR201802323T4 (enExample) |
| WO (1) | WO2009076524A2 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2611056C (en) | 2005-06-01 | 2016-06-28 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| BRPI0714495B8 (pt) | 2006-07-21 | 2021-05-25 | California Inst Of Techn | lentivírus deficiente para replicação recombinante pseudotipado |
| TR201802323T4 (tr) | 2007-12-11 | 2018-03-21 | Univ North Carolina Chapel Hill | Polipürin yolu modifiye edilmiş retroviral vektörler. |
| KR101790187B1 (ko) | 2009-07-24 | 2017-10-25 | 이뮨 디자인 코포레이션 | 신드비스 바이러스 외피 당단백질로 가성형태화된 렌티바이러스 벡터 |
| US20120263754A1 (en) | 2011-02-15 | 2012-10-18 | Immune Design Corp. | Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines |
| AU2012243039B2 (en) | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| DK2831095T3 (en) | 2012-03-30 | 2019-02-18 | Immune Design Corp | LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN |
| PT2850431T (pt) | 2012-05-16 | 2018-07-23 | Immune Design Corp | Vacinas para hsv-2 |
| WO2015123496A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| KR20170032373A (ko) | 2014-07-15 | 2017-03-22 | 이뮨 디자인 코포레이션 | Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법 |
| KR101607282B1 (ko) | 2014-12-18 | 2016-03-29 | 충남대학교산학협력단 | 유리형 산화환원조절단백-1 및 이를 함유하는 항염증 약학조성물 |
| JP6734283B2 (ja) | 2015-01-21 | 2020-08-05 | フレッド ハッチンソン キャンサー リサーチ センター | 遺伝子治療用ポイントオブケア及び／又はポータブルプラットフォーム |
| WO2017066570A1 (en) * | 2015-10-15 | 2017-04-20 | The University Of North Carolina At Chapel Hill | Methods and compositions for integration-defective lentiviral vectors |
| HK1258932A1 (zh) | 2015-10-22 | 2019-11-22 | Juno Therapeutics Gmbh | 用於转导的方法、反应剂盒、反应剂和设备 |
| CA3004132A1 (en) | 2015-11-09 | 2017-05-18 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids |
| SG11201803546WA (en) | 2015-11-09 | 2018-05-30 | Immune Design Corp | Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof |
| KR20180111874A (ko) | 2016-02-23 | 2018-10-11 | 이뮨 디자인 코포레이션 | 멀티게놈 레트로바이러스 벡터 제제 및 이를 생산 및 사용하는 방법 및 시스템 |
| IL310729A (en) | 2016-04-15 | 2024-04-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins that are variants of CD80 and their uses |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| CA3031994A1 (en) | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Methods for assessing the presence or absence of replication competent virus |
| MA46998A (fr) | 2016-12-05 | 2019-10-09 | Juno Therapeutics Inc | Production de cellules modifiées pour une thérapie cellulaire adoptive |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| EP3596114A2 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| IL320149A (en) | 2017-03-16 | 2025-06-01 | Alpine Immune Sciences Inc | Pd-l1 variant immunomodulatory proteins and uses thereof |
| KR20200064060A (ko) | 2017-07-29 | 2020-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 세포 증폭용 시약 |
| AU2018313950A1 (en) | 2017-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Methods for producing genetically engineered cell compositions and related compositions |
| WO2019074983A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| MA50855A (fr) | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | Procédé de génération de compositions thérapeutiques de cellules modifiées |
| MA50859A (fr) | 2017-11-01 | 2020-09-09 | Celgene Corp | Procédé pour la production d'une composition de lymphocytes t |
| JP7433230B2 (ja) | 2017-12-08 | 2024-02-19 | ジュノー セラピューティクス インコーポレイテッド | 細胞を培養するための無血清培地配合物およびその使用の方法 |
| WO2019136179A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| WO2019152747A1 (en) | 2018-01-31 | 2019-08-08 | Juno Therapeutics, Inc. | Methods and reagents for assessing the presence or absence of replication competent virus |
| US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
| KR20210089146A (ko) | 2018-09-19 | 2021-07-15 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 변이체 cd80 단백질 및 관련 구축물의 방법 및 용도 |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| EP3880238A1 (en) | 2018-11-16 | 2021-09-22 | Juno Therapeutics, Inc. | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| SG11202105380RA (en) | 2018-11-30 | 2021-06-29 | Juno Therapeutics Inc | Methods for dosing and treatment of b cell malignancies in adoptive cell therapy |
| JP7713886B2 (ja) | 2018-11-30 | 2025-07-28 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｄ８６バリアント免疫調節タンパク質およびその使用 |
| BR112021010354A2 (pt) | 2018-11-30 | 2021-11-03 | Juno Therapeutics Inc | Métodos para o tratamento usando terapia celular adotiva |
| KR20220035032A (ko) | 2019-04-17 | 2022-03-21 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 변이체 icos 리간드(icosl) 융합 단백질의 방법 및 용도 |
| MX2021015125A (es) | 2019-06-07 | 2022-04-06 | Juno Therapeutics Inc | Cultivo automatizado de celulas t. |
| US20220249637A1 (en) | 2019-06-12 | 2022-08-11 | Juno Therapeutics, Inc. | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| CN115087868A (zh) | 2019-11-05 | 2022-09-20 | 朱诺治疗学股份有限公司 | 确定治疗性t细胞组合物的属性的方法 |
| WO2021113770A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Methods related to toxicity and response associated with cell therapy for treating b cell malignancies |
| KR20220145341A (ko) | 2020-01-24 | 2022-10-28 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법에서 여포성 림프종 및 변연부 림프종의 투여 및 치료 방법 |
| KR20220146480A (ko) | 2020-01-28 | 2022-11-01 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｔ 세포 형질도입 방법 |
| IL297147B1 (en) | 2020-04-10 | 2026-05-01 | Juno Therapeutics Inc | Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen |
| WO2021226551A1 (en) | 2020-05-08 | 2021-11-11 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins and methods of use thereof |
| WO2021231657A1 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| KR20230085929A (ko) | 2020-10-15 | 2023-06-14 | 에프. 호프만-라 로슈 아게 | Va rna 전사를 위한 핵산 구조체 |
| WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
| KR20230159851A (ko) | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 결정하는 방법 |
| KR20230158573A (ko) | 2021-03-22 | 2023-11-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 바이러스 벡터 입자의 효력을 평가하는 방법 |
| WO2022212400A1 (en) | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| EP4333869A1 (en) | 2021-05-07 | 2024-03-13 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
| US20250243260A1 (en) | 2022-03-07 | 2025-07-31 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| CN120344256A (zh) | 2022-10-04 | 2025-07-18 | 高山免疫科学股份有限公司 | 突变的taci-fc融合蛋白用于在治疗自身抗体介导的疾病中的用途 |
| EP4698902A1 (en) | 2023-04-18 | 2026-02-25 | Juno Therapeutics, Inc. | Cytotoxicity assay for assessing potency of therapeutic cell compositions |
| WO2024226858A1 (en) | 2023-04-26 | 2024-10-31 | Juno Therapeutics, Inc. | Methods for viral vector manufacturing |
| EP4716851A2 (en) | 2023-05-23 | 2026-04-01 | Juno Therapeutics, Inc. | Activation markers of t cells and method for assessing t cell activation |
| WO2024263991A2 (en) * | 2023-06-22 | 2024-12-26 | Arc Research Institute | Methods and compositions for integration deficient viral vectors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861161A (en) | 1994-09-07 | 1999-01-19 | Universite De Montreal | Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions |
| NZ324157A (en) * | 1995-11-28 | 2000-10-27 | Univ Johns Hopkins Med | Conditionally replicating viral vectors and their use in treating HIV |
| WO2001030965A2 (en) | 1999-10-28 | 2001-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of in vivo gene transfer using a sleeping beauty transposon system |
| US6673567B2 (en) | 2000-03-23 | 2004-01-06 | E. I. Du Pont De Nemours And Company | Method of determination of gene function |
| WO2002042482A2 (en) * | 2000-11-27 | 2002-05-30 | Chiron Corporation | Functional lentiviral vector from an mlv-based backbone |
| WO2004022761A1 (en) | 2002-09-03 | 2004-03-18 | Oxford Biomedica (Uk) Limited | Retroviral vector and stable packaging cell lines |
| US7220578B2 (en) * | 2002-11-27 | 2007-05-22 | Tal Kafri | Single LTR lentivirus vector |
| EP2055316A1 (en) * | 2003-09-09 | 2009-05-06 | VIRxSYS Corporation | Lentivirus vector-based approaches for generating an immune response to HIV in humans |
| GB0325379D0 (en) | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
| WO2005056057A1 (en) * | 2003-12-04 | 2005-06-23 | Childrens Hospital Los Angeles Research Institute | Minimal lentiviral vector system |
| JP2007054069A (ja) * | 2005-08-24 | 2007-03-08 | Medizinische Hochschule Hannover | 自己不活性化レトロウイルスベクター |
| EP1757703A3 (en) | 2005-08-24 | 2007-12-05 | Medizinische Hochschule Hannover | Self-inactivating retroviral vector |
| TR201802323T4 (tr) | 2007-12-11 | 2018-03-21 | Univ North Carolina Chapel Hill | Polipürin yolu modifiye edilmiş retroviral vektörler. |
-
2008
- 2008-12-11 TR TR2018/02323T patent/TR201802323T4/tr unknown
- 2008-12-11 SI SI200831929T patent/SI2222861T1/en unknown
- 2008-12-11 HR HRP20180184TT patent/HRP20180184T1/hr unknown
- 2008-12-11 PL PL08859393T patent/PL2222861T3/pl unknown
- 2008-12-11 PT PT88593934T patent/PT2222861T/pt unknown
- 2008-12-11 US US12/747,076 patent/US9796987B2/en active Active
- 2008-12-11 NO NO08859393A patent/NO2222861T3/no unknown
- 2008-12-11 JP JP2010538155A patent/JP5749014B2/ja not_active Expired - Fee Related
- 2008-12-11 DK DK08859393.4T patent/DK2222861T3/en active
- 2008-12-11 RS RS20180107A patent/RS56844B1/sr unknown
- 2008-12-11 HU HUE08859393A patent/HUE036103T2/hu unknown
- 2008-12-11 EP EP08859393.4A patent/EP2222861B1/en active Active
- 2008-12-11 WO PCT/US2008/086409 patent/WO2009076524A2/en not_active Ceased
- 2008-12-11 ES ES08859393.4T patent/ES2664988T3/es active Active
- 2008-12-11 LT LTEP08859393.4T patent/LT2222861T/lt unknown
- 2008-12-11 EP EP17204678.1A patent/EP3342872A1/en not_active Withdrawn
-
2015
- 2015-01-28 JP JP2015013974A patent/JP6001702B2/ja not_active Expired - Fee Related
-
2017
- 2017-10-23 US US15/790,530 patent/US10017785B2/en active Active
-
2018
- 2018-02-09 CY CY20181100167T patent/CY1119905T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8828718B2 (en) | Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements | |
| Park | Lentiviral vectors: are they the future of animal transgenesis? | |
| Delenda | Lentiviral vectors: optimization of packaging, transduction and gene expression | |
| KR102091957B1 (ko) | 레트로바이러스 생산을 위한 안정한 세포주 | |
| JP6001702B2 (ja) | ポリプリントラクト改変レトロウイルスベクター | |
| Wiznerowicz et al. | Harnessing HIV for therapy, basic research and biotechnology | |
| Chang et al. | The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors | |
| CN105705645B (zh) | 逆转录病毒载体 | |
| Pluta et al. | Use of HIV as a gene transfer vector | |
| Hauber et al. | Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice | |
| CN113302291B (zh) | 使用逆转录病毒整合酶-Cas9融合蛋白通过定向非同源DNA插入进行的基因组编辑 | |
| JP2006524051A (ja) | 両方向性合成プロモーターを備えたレンチウイルスベクターおよびその使用 | |
| JP6878620B2 (ja) | レトロウイルス産生のための安定な細胞株 | |
| WO2004056966A2 (en) | Methods of inhibiting gene expression by rna interference | |
| Lois et al. | Retroviruses as tools to study the immune system | |
| CN105543223A (zh) | 一种基于miRNA/shRNA转录加工机制转录sgRNA的方法 | |
| Liu et al. | Enhancement of cell‐specific transgene expression from a Tet‐Off regulatory system using a transcriptional amplification strategy in the rat brain | |
| Dehdilani et al. | Genetically engineered birds; pre-CRISPR and CRISPR era | |
| CN116867901A (zh) | 功能性核酸分子和方法 | |
| Everson et al. | Retroviral vector interactions with hematopoietic cells | |
| Goyvaerts et al. | Targeted lentiviral vectors: current applications and future potential | |
| Fang et al. | Application advances of lentiviral vectors: From gene therapy to vaccine development | |
| CN105274089B (zh) | 一种表达绿色荧光囊膜融合蛋白的rev病毒传染性克隆的构建方法 | |
| RU2013115637A (ru) | Усовершенствование генетических конструкций для повышения эффективности антивич терапии | |
| US20240352485A1 (en) | Compositions and methods for the production of libraries |